Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 12/20 | 0.63 |
| ▸ | SCN7A | Q01118 | 8/20 | 0.56 |
| ▸ | SCN5A | Q14524 | 8/20 | 0.56 |
| ▸ | SCN1A | P35498 | 1/20 | 0.49 |
| ▸ | SCN4A | P35499 | 1/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.49 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.49 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20697825 | 0.95 | SCN9A (0.63) | SCN9ASCN7ASCN5ASCN1ASCN4A | |
| SCHEMBL21075275 | 0.95 | SCN9A (0.63) | SCN9ASCN7ASCN5ASCN1ASCN4A | |
| SCHEMBL17422988 | 0.94 | SCN9A (0.63) | SCN9ASCN7ASCN5ASCN1ASCN4A | |
| SCHEMBL17422991 | 0.94 | SCN9A (0.63) | SCN9ASCN7ASCN5ASCN1ASCN4A | |
| SCHEMBL19083860 | 0.92 | SCN7A (0.57) | SCN9ASCN7ASCN5ASCN1ASCN4A | |
| SCHEMBL17428592 | 0.89 | SCN9A (0.80) | SCN9ASCN7ASCN5ASCN1ASCN4A | |
| SCHEMBL19084038 | 0.88 | SCN9A (0.64) | SCN9ASCN7ASCN5ASCN1ASCN4A | |
| SCHEMBL21075361 | 0.88 | SCN9A (0.64) | SCN9ASCN7ASCN5ASCN1ASCN4A | |
| SCHEMBL17428455 | 0.88 | SCN9A (0.66) | SCN9ASCN7ASCN5ASCN1ASCN4A | |
| SCHEMBL19064894 | 0.88 | SCN9A (0.66) | SCN9ASCN7ASCN5ASCN1ASCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| WO-2016007534-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | SCN9A 2337/4885SCN7A 1926/4885SCN5A 1598/4885 |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | SCN9A 2337/4885SCN7A 1926/4885SCN5A 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.